07/06/2022 – AB Science today announced the publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids (OCS) in the peer-reviewed Journal of Asthma and Allergy Download PDF Post navigationPreviousPrevious post:AB Science announces that Health Canada has started the review of New Drug Submission for masitinib in the treatment of ALSNextNext post:AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALSRelated PostsAB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s DiseaseNovember 21, 2022AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s diseaseOctober 10, 2022Revenues for the first half of 2022 and update on AB Science’s activitiesSeptember 30, 2022Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating the antiviral activity of masitinib in Covid-19September 14, 2022AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALSAugust 24, 2022AB Science announces that Health Canada has started the review of New Drug Submission for masitinib in the treatment of ALSMay 26, 2022
AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s DiseaseNovember 21, 2022
AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s diseaseOctober 10, 2022
Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating the antiviral activity of masitinib in Covid-19September 14, 2022
AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALSAugust 24, 2022
AB Science announces that Health Canada has started the review of New Drug Submission for masitinib in the treatment of ALSMay 26, 2022
